Foscarnet therapy in five patients with AIDS and acyclovir-resistant varicella-zoster virus infection
| Autor: | Karen K. Biron, Peter R. Wolfe, Ian Gilson, John Mills, Sharon Safrin, Constance B. Wofsy, Timothy G. Berger |
|---|---|
| Rok vydání: | 1991 |
| Předmět: |
Foscarnet
Adult Phosphonoacetic Acid Herpesvirus 3 Human viruses medicine.medical_treatment Mucocutaneous zone Acyclovir Varicella-zoster virus infection Antiviral Agents Herpes Zoster Cohort Studies Acquired immunodeficiency syndrome (AIDS) Immunopathology Internal Medicine medicine Humans Skin Diseases Infectious Chemotherapy Acquired Immunodeficiency Syndrome integumentary system business.industry virus diseases Drug Resistance Microbial General Medicine biochemical phenomena metabolism and nutrition Middle Aged medicine.disease Virology Thymidine kinase Immunology Viral disease business medicine.drug |
| Zdroj: | Annals of internal medicine. 115(1) |
| ISSN: | 0003-4819 |
| Popis: | To determine whether foscarnet has potential efficacy in the treatment of acyclovir-resistant mucocutaneous varicella-zoster infection in patients with the acquired immunodeficiency syndrome (AIDS).Open-label study.Three university medical centers.Five patients with AIDS who were infected with thymidine-kinase-deficient or -altered strains of varicella-zoster virus.Foscarnet, 40 mg/kg body weight every 8 hours in 1-hour infusions for 10 or more days.Four patients had healing in response to foscarnet therapy, and each of four tested patients became culture negative for virus during foscarnet therapy. Results of fluorescent antigen testing remained positive during therapy in two patients; one of these patients had concomitant clinical failure but the other patient healed fully. One patient had complete healing despite the emergence of resistance to foscarnet in serial specimens obtained during foscarnet therapy.Foscarnet is a potentially effective and tolerable antiviral agent for patients with acyclovir-resistant, varicella-zoster virus infection; however, the optimal dosage and duration of therapy require further study, as does the relation between clinical findings and in-vitro susceptibility results. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|